Search
Potassium carbonate
go.drugbank.com/drugs/DB13977ApprovedPotassium carbonate (K2CO3) is a white salt, soluble in water (insoluble in ethanol) which forms a strongly alkaline solution. … It presents a large capacity to absorb moisture.
Mixtures: Buffered Vitamin C Powder With Ca Mg and KLercanidipine
go.drugbank.com/drugs/DB00528ApprovedInvestigationalWithdrawnLercanidipine is a calcium channel blocker of the dihydropyridine class. It is sold under various commercial names including Zanidip.
Mixtures: ENALAPRIL/LERCA AL 10/10MG, ENALAPRIL/LERCA AL 10/10MGProducts: LERCANIDIPIN-HCL AL 10MG, LERCANIDIPIN-HCL AL 20MGNivolumab
go.drugbank.com/drugs/DB09035ApprovedInvestigationalNivolumab is a fully human IgG4 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1).
Categories: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitorsRelatlimab
go.drugbank.com/drugs/DB14851ApprovedInvestigationalRelatlimab is a human IgG4 monoclonal antibody and novel immune checkpoint inhibitor that targets lymphocyte activation gene-3 (LAG-3). … [L41265,L41300] It was the first anti-LAG-3 antibody to demonstrate benefit in a Phase 3 study, as well as the first to receive FDA approval.
Stavudine
go.drugbank.com/drugs/DB00649ApprovedInvestigationalA dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV.
Mixtures: COVIRO ® LSPenpulimab
go.drugbank.com/drugs/DB16747ApprovedInvestigationalPenpulimab is a humanized monoclonal IgG1 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1). … [A273848] In order to further reduce the risk of toxicities and improve efficacy, penpulimab was designed with Fc mutations in order to eliminate Fc receptor and complement-mediated effector function,
Categories: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitorsPibrentasvir
go.drugbank.com/drugs/DB13878ApprovedInvestigationalIndividual NS5A amino acid substitutions that reduced susceptibility to pibrentasvir include M28G or Q30D in a genotype 1a replicon and P32-deletion in a genotype 1b replicon [L940]. … In cell cultures, the emergence of amino acid substitutions at known NS5A inhibitor resistance-associated positions in HCV genotype 1a, 2a or 3a replicons led to reduced susceptibility and resistance to
Cemiplimab
go.drugbank.com/drugs/DB14707ApprovedInvestigationalCemiplimab is a fully human monoclonal antibody that works against programmed death receptor-1 (PD-1), which is a negative regulator of T cell function.
Categories: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitorsSugemalimab
go.drugbank.com/drugs/DB16641ApprovedInvestigationalSugemalimab is a fully human, full-length anti-programmed death-ligand 1 (PD-L1) monoclonal antibody (of the IgG4 isotype) discovered by CStone Pharmaceuticals. … [L53333] The drug achieves this through a dual mechanism of action involving binding to the programmed cell death-ligand 1 (PD-L1) and also through inducing antibody-dependent cellular phagocytosis.
Categories: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitorsOmega-3-carboxylic acids
go.drugbank.com/drugs/DB09568ApprovedWithdrawnThe omega-3 carboxylic acid (OM3-CA) is a new formulation of omega-3 fatty acids that present an enhanced bioavailability in the treatment of dyslipidemia. … The increased bioavailability is explained because OM3-CA is found in a form of polyunsaturated free fatty acids as opposed to other products whose form is as ethyl esters.